Endo to purchase Par Pharmaceutical for US$8.05bn

Published: 19-May-2015
Finance Pharmaceutical

Expanding generics business, product portfolio, pipeline and manufacturing capabilities


Endo International, which has its global headquarters in Dublin, Ireland, is to buy privately held Par Pharmaceutical Holdings for US$8.05bin, in a move that will significantly expand Endo's generics business as well as driving long-term revenue growth.

The transaction has been unanimously approved by both Boards of Directors and is expected to be completed in the second half of this year. Endo will pay around $1.55bn (18 million shares) in equity and $6.50bn in cash to Par shareholders.

Rajiv De Silva, President and CEO of Endo said: 'This transaction with Par builds upon our generics growth, adding a strong portfolio of high barrier-to-entry and attractive gross margin products while also transforming Endo, creating a powerful corporate platform for future growth and strategic M&A.'

Par Chief Executive Paul Campanelli will join Endo to lead the generics business. He said the two companies share the same goal of 'developing and commercialising generic drugs in areas of greatest revenue potential, complex formulations and longer life cycles.'

  • Companies:
  • Par Pharmaceutical Companies
  • Endo Pharmaceuticals
See more

You may also like

Finance

Endo buys portfolio of branded and generic products

Read more
Acquisition supports continued growth in South Africa and adds some 60 on-market products and nearly 70 R&D pipeline programmes

Trending Articles

  1. Lonza Capsules & Health Ingredients expands capsule manufacturing capacity in India and China New capsule manufacturing lines added at Lonza Capsules & Health Ingredients (CHI) facilities in Rewari (IN) and Suzhou (CN), highlighting the long-term strategic commitment to the business and the APAC region
  2. Novo Holdings completes acquisition of Catalent Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark
  3. ACG expands global footprint with new capsule manufacturing facility in Thailand New capsule manufacturing facility in Rayong, Thailand, is strategically positioned to serve key Asian markets
  4. Newcells Biotech raises additional funding from investors Newcells Biotech, a leading drug discovery partner specialising in the development of in vitro models and bespoke assay services to improve the prediction of in vivo human outcomes, has raised a further £1.2m from existing investors Mercia Ventures, Northstar Ventures and North East Finance
  5. The colouration of tablets and capsules Paul Smith from Sensient Pharmaceutical Technologies discusses the use of colour in solid oral dosage forms

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Finance

Endo buys portfolio of branded and generic products

Acquisition supports continued growth in South Africa and adds some 60 on-market products and nearly 70 R&D pipeline programmes
Finance

Valeant increases offer for Salix to US$15.8bn in cash

Endo withdraws its offer for the US manufacturer of gastrointestinal drugs
Finance

Endo submits offer to purchase Salix Pharmaceuticals for about US$15.7bn

Higher bid than Valeant's offer of $14.5bn in February
Finance

Endo to acquire DAVA Pharmaceuticals

Adds high-margin generics portfolio and robust near-term ANDA pipeline to Endo\'s existing generics portfolio
Finance

Endo to buy Mexican speciality pharmaceuticals company Somar

Adds a strong growth platform in Mexico, a proven sales team and scalable manufacturing facilities
Manufacturing

Par Pharmaceutical to buy JHP Pharmaceuticals

Adds sterile injectable products to its portfolio
Finance

Endo to buy Paladin Labs for US$1.6bn

The firm will expand its presence in Canada and emerging markets
Subscribe now